The global embolotherapy industry is experiencing growth and is projected to reach 6,447.1 million by 2030, according to P&S Intelligence. This growth can be ascribed to the rising patient pool, mounting occurrence of chronic and lifestyle-related illnesses, growing healthcare investments, and advancing healthcare infrastructure.
 |
| To learn more about this report: https://bit.ly/43NzT3S |
In recent years, embolic agents led the industry, on the basis of product. The growing utilization of embolic agents in numerous interventional radiology procedures is the major factor for this product category's supremacy in the industry.
Moreover, because of the improvements in such agents, including drug-eluting microspheres, standardized microspheres for bland embolization, and radioactive yttrium-90 (Y-90) microspheres, for curing primary or secondary liver illness, the category is projected to advance at a higher rate in the coming few years.
In recent years, North America led the embolotherapy market, and it is projected to grip the largest industry share in the future as well. The growing occurrence of signs that need embolization procedures, well-known healthcare infrastructure, and the growth of progressive embolic agents by the players functioning in the continent are some of the key factors for the development of the North American industry.
The extended exposure to four modifiable lifestyle behaviors, mainly physical inactivity, smoking, alcohol consumption, and unhealthy diet, commonly results in chronic illnesses, such as diabetes, stroke, metabolic syndrome, obesity, chronic obstructive pulmonary illness, and numerous kinds of cancer.
Chronic illnesses are a key healthcare load impacting high-income as well as low- and middle-income nations (LMICs). Hepatitis, cancer, and central nervous system syndromes are some of the chronic illnesses that need progressive treatment. Therefore, the surge in the occurrence of chronic and lifestyle-related illnesses is boosting the embolotherapy industry worldwide.
Hence, the growing patient pool, mounting occurrence of chronic and lifestyle-related illnesses, growing healthcare investments, and advancing healthcare infrastructure, such factors are propelling embolotherapy market.
